Dihydrotanshinone I inhibits ovarian tumor growth by activating oxidative stress through Keap1-mediated Nrf2 ubiquitination degradationABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells. This evidence concerns the gene KEAP1 and ovarian carcinoma.